A detailed history of Citigroup Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 200,519 shares of NBIX stock, worth $27.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
200,519
Previous 116,289 72.43%
Holding current value
$27.4 Million
Previous $16 Million 44.2%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $9.65 Million - $12.9 Million
84,230 Added 72.43%
200,519 $23.1 Million
Q2 2024

Aug 12, 2024

SELL
$130.86 - $143.19 $5.08 Million - $5.55 Million
-38,789 Reduced 25.01%
116,289 $16 Million
Q1 2024

May 10, 2024

SELL
$130.4 - $143.74 $2.2 Million - $2.42 Million
-16,855 Reduced 9.8%
155,078 $21.4 Million
Q4 2023

Feb 09, 2024

SELL
$106.07 - $132.76 $1.9 Million - $2.38 Million
-17,915 Reduced 9.44%
171,933 $22.7 Million
Q3 2023

Nov 09, 2023

SELL
$94.02 - $117.1 $1.81 Million - $2.26 Million
-19,273 Reduced 9.22%
189,848 $21.4 Million
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $865,396 - $1.01 Million
-9,666 Reduced 4.42%
209,121 $19.7 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $7.61 Million - $9.94 Million
80,811 Added 58.57%
218,787 $22.1 Million
Q4 2022

Feb 09, 2023

BUY
$106.72 - $127.06 $255,060 - $303,673
2,390 Added 1.76%
137,976 $16.5 Million
Q3 2022

Nov 10, 2022

BUY
$92.03 - $107.81 $3.74 Million - $4.39 Million
40,677 Added 42.86%
135,586 $14.4 Million
Q2 2022

Aug 10, 2022

BUY
$75.79 - $100.07 $2.51 Million - $3.31 Million
33,104 Added 53.56%
94,909 $9.25 Million
Q1 2022

May 12, 2022

SELL
$72.45 - $94.81 $3.26 Million - $4.26 Million
-44,956 Reduced 42.11%
61,805 $5.79 Million
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $3.45 Million - $4.6 Million
43,336 Added 68.33%
106,761 $9.09 Million
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $5.47 Million - $6.28 Million
63,425 New
63,425 $6.08 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.